MA56549A - Méthode de traitement d'une tumeur maligne - Google Patents

Méthode de traitement d'une tumeur maligne

Info

Publication number
MA56549A
MA56549A MA056549A MA56549A MA56549A MA 56549 A MA56549 A MA 56549A MA 056549 A MA056549 A MA 056549A MA 56549 A MA56549 A MA 56549A MA 56549 A MA56549 A MA 56549A
Authority
MA
Morocco
Prior art keywords
treating
malignant tumor
malignant
tumor
Prior art date
Application number
MA056549A
Other languages
English (en)
French (fr)
Inventor
Kazuo Koba
Toshiyasu Shimomura
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA56549A publication Critical patent/MA56549A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
MA056549A 2019-06-21 2020-06-19 Méthode de traitement d'une tumeur maligne MA56549A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019115496 2019-06-21

Publications (1)

Publication Number Publication Date
MA56549A true MA56549A (fr) 2022-04-27

Family

ID=74040503

Family Applications (1)

Application Number Title Priority Date Filing Date
MA056549A MA56549A (fr) 2019-06-21 2020-06-19 Méthode de traitement d'une tumeur maligne

Country Status (8)

Country Link
US (1) US20220354858A1 (https=)
EP (1) EP3988175A4 (https=)
JP (1) JP7574184B2 (https=)
KR (1) KR20220024821A (https=)
AU (1) AU2020297166A1 (https=)
MA (1) MA56549A (https=)
TW (1) TWI856115B (https=)
WO (1) WO2020256096A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3424505A4 (en) 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
SG11202008435SA (en) 2018-03-19 2020-10-29 Taiho Pharmaceutical Co Ltd Pharmaceutical composition including sodium alkyl sulfate
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101658274B1 (ko) 2011-04-06 2016-09-22 다이호야쿠힌고교 가부시키가이샤 신규 이미다조 옥사진 화합물 또는 그의 염
DK2657233T3 (da) 2012-01-19 2014-09-22 Taiho Pharmaceutical Co Ltd 3,5-disubstitueret alkynylbenzenforbindelse og salt deraf
NO2868660T3 (https=) * 2012-07-02 2018-05-26
JP6289459B2 (ja) 2013-06-20 2018-03-07 大鵬薬品工業株式会社 ＰＨＬＤＡ１又はＰＩＫ３Ｃ２Ｂの発現に基づくＰＩ３Ｋ／ＡＫＴ／ｍＴＯＲ阻害剤の治療効果の予測方法
CN111943962A (zh) * 2015-02-27 2020-11-17 大鹏药品工业株式会社 咪唑并噁嗪晶体、含有所述晶体的药物组合物和制备所述晶体的方法
EP3424505A4 (en) * 2016-03-04 2019-10-16 Taiho Pharmaceutical Co., Ltd. PREPARATION AND COMPOSITION FOR THE TREATMENT OF MALIGNANT TUMORS
US11883404B2 (en) 2016-03-04 2024-01-30 Taiho Pharmaceuticals Co., Ltd. Preparation and composition for treatment of malignant tumors
EP4093406A4 (en) * 2020-01-24 2024-02-28 Taiho Pharmaceutical Co., Ltd. IMPROVEMENT OF THE ANTI-TUMORAL ACTIVITY OF SHP2 INHIBITOR PYRIMIDINONE IN COMBINATION WITH NEW ANTI-CANCER DRUGS AGAINST CANCER
EP4284378A4 (en) * 2021-02-01 2024-12-25 Taiho Pharmaceutical Co., Ltd. Ptentreating cancer in patient with pten inactivating mutation

Also Published As

Publication number Publication date
TW202114691A (zh) 2021-04-16
US20220354858A1 (en) 2022-11-10
JPWO2020256096A1 (https=) 2020-12-24
WO2020256096A1 (ja) 2020-12-24
TWI856115B (zh) 2024-09-21
AU2020297166A1 (en) 2022-02-17
EP3988175A4 (en) 2023-06-28
KR20220024821A (ko) 2022-03-03
JP7574184B2 (ja) 2024-10-28
EP3988175A1 (en) 2022-04-27

Similar Documents

Publication Publication Date Title
MA56549A (fr) Méthode de traitement d'une tumeur maligne
EP3959218A4 (en) PRODRUGS OF A CDK INHIBITOR FOR THE TREATMENT OF CANCER
EP3352761A4 (en) METHOD FOR THE TREATMENT OF MALIGNEM RHABDOIDEM TUMOR OF OVARIA (MRTO) / SMALL CELL CARCINOMA OF THE HYPER-CALCEMIC TYPE OVARIA (SCCOHT) WITH AN EZH2 INHIBITOR
MA56508A (fr) Inhibiteur d'egfr pour le traitement du cancer
EP3778649A4 (en) METHOD AND COMPOSITION FOR THE TREATMENT OF TUMORS
MA54388A (fr) Méthodes de traitement du cancer résistant aux inhibiteurs cdk4/6
EP4034128A4 (en) Method for inducing tumor regression
EP3952858A4 (en) METHODS OF TREATMENT OF TUMOR
EP3782618A4 (en) METHODS OF PREVENTING OR TREATMENT OF SIDE EFFECTS OF CANCER THERAPY
MA47408B1 (fr) Traitement du cancer
EP3775171A4 (en) METHODS OF TREATMENT OF MINIMAL RESIDUAL CANCER
IL285352A (en) Anti-nme antibody and method of treating cancer or cancer metastasis
EP3774785A4 (en) METHODS FOR TREATMENT OF FIBROTIC DISEASES
EP3644062C0 (en) METHOD FOR PREDICTING THE RESPONSE OF ESOPIAL CANCER TO ANTI-ERBB3 ANTIBODIES THERAPY
EP3834849A4 (en) METHOD OF TREATMENT OF A TUMOR USING AN IMMUNE EFFECTOR CELL
EP3672689A4 (en) METHOD OF TREATMENT OF A NEUROENDOCRINE TUMOR
MA54827A (fr) Méthodes de traitement d'une maladie à l'aide d'inhibiteurs de magl
EP3920895A4 (en) PROCEDURES FOR THE PREVENTION OR TREATMENT OF TREATMENT-RELATED GASTROINTESTINAL INJURIES
IL289811A (en) A method for treating cancer
EP3810107A4 (en) METHOD OF TREATMENT OF AN ALLERGIC DISEASE
SG11202107017TA (en) Methods of treating cancer
EP3412295A4 (en) METHOD FOR THE TREATMENT OF CANCER PATIENTS WITH HEAVY NIER FUNCTION TROUBLESHOOTING
EP3773693A4 (en) METHODS OF TREATMENT OF AUTOIMMUNE DISEASES
EP4321868A4 (en) Method for treating cancer using immune checkpoint inhibitor
EP3958892A4 (en) METHOD OF TREATMENT OF LIVER DISEASE